Hemispherx Biopharma
Pharmaceutical Manufacturing • 
Marion Oaks, Florida, United States • 21-50 Employees
Company overview
| Headquarters | 2117 SW Highway 484, Ocala, Florida, US |
| Phone number | +13524487797 |
| Websites | |
| NAICS | 3254 |
| SIC | 283 |
| Founded | 1966 |
| Employees | 21-50 |
| Socials |
Key Contacts at Hemispherx Biopharma
Nancy Mcgrory
Managing Director Communications & Advocacy
Laurie Santos
Associate Director Of Administration
Nancy Schocklin
Director Of Human Resources
Brian Smith
Associate Director Of Manufacturing
Benjamin Sangalli
Director
Hemispherx Biopharma Email Formats
Hemispherx Biopharma uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@hemispherx.net), used 81.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@hemispherx.net | 81.2% |
{first name} | john@hemispherx.net | 12.5% |
{first initial} | j@hemispherx.net | 6.2% |
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
Hemispherx Biopharma revenue & valuation
| Annual revenue | $500,000 |
| Revenue per employee | $11,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $1,600,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Hemispherx Biopharma has 25 employees across 10 departments.
Departments
Number of employees
Funding Data
Hemispherx Biopharma has never raised funding before.
Canada
United Kingdom
Denmark
Australia
Frequently asked questions
4.8
40,000 users
